Gill, Jason - Durham University - School of Medicine, Pharmacy & Health, Pharmacy

研究领域

Cancer Drug Discovery and Development Endoproteases as Drug Targets Safety Assessment of Cancer Therapeutics Molecular pharmacology Matrix metalloproteinase

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Cross, J.M., Blower, T.R., Gallagher, N., Gill, J.H., Rockley, K.L. & Walton, J.W. (2016). Anticancer RuII and RhIII Piano-Stool Complexes that are Histone Deacetylase Inhibitors. ChemPlusChem 81. Jamie, K., Bows, H. & Gill, J. (2016). Integration of pharmacogenetic principles as a core thread in the undergraduate pharmacy curriculum. Pharmacy Education 16(1): 64-66. Cross, J.M., Gallagher, N., Gill, J.H., Jain, M., McNeillis, A.W., Rockley, K.L., Tscherny, F.H., Wirszycz, N.J., Yufit, D.S. & Walton, J.W. (2016). Pyridylphosphinate Metal Complexes: Synthesis, Structural Characterisation and Biological Activity. Dalton Transactions 45(32): 12807-12813. Ansari, C., Tikhomirov, G.A., Hong, S.H., Falconer, R.A., Loadman, P.M., Gill, J.H., Castaneda, R., Hazard, F.K., Tong, L., Lenkov, O.D., Felsher, D.W., Rao, J. & Daldrup-Link, H.E. (2014). Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy. Small 10(3): 566-575. Gill, J.H., Loadman, P.M., Shnyder, S.D., Cooper, P., Atkinson, J.M., Ribeiro Morais, G., Patterson, L.H. & Falconer, R.A. (2014). The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity. Molecular Pharmaceutics 11(4): 1294-1300. Sutherland, M, Gill, J.H, Loadman, P.M, Laye, J.P, Sheldrake, H.M, Illingworth, N.A, Alandas, M.N, Cooper, P.A, Searcey, M, Pors, K, Shnyder, S.D & Patterson, L.H (2013). Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Molecular Cancer Therapeutics 12(1): 27-37. O'Farrell, AC, Shnyder, SD, Marston, G, Colletta, L & Gill, JH (2013). Non-invasive molecular imaging for preclinical cancer therapeutic development. British Journal of Pharmacology 169(4): 719-735. Boissinot, M, Inman, M, Hempshall, A, James, S.R, Gill J.H, Selby, P, Bowen, D.T, Grigg, R.E & Cockerill, P.N (2012). Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. Leukemia Research 36(10): 1304-1310. Atkinson, J.M, Falconer, R.A, Edwards, D.R., Pennington, C.J., Siller, C.S., Shnyder, S.D., Bibby, M.C., Patterson, L.H, Loadman, P.M & Gill, J.H (2010). Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-Type Matrix Metalloproteinases. Cancer Research 70(17): 6902-6912. Mardaryev, A.N, Ahmed, M.I, Vlahov, N.V, Fessing, M.Y, Gill, J.H, Sharov, A.A & Botchkareva, N.V (2010). Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB Journal 24(10): 3869-3881. Krippner-Heidenreich, A, Grunwald, I, Zimmermann, G, Kühnle, M, Gerspach, J, Sterns, T, Shnyder, S, Gill, J.H, M?nnel, D, Pfizenmaier, K & Scheurich, P (2008). Single chain TNF, a TNF derivative with enhanced stability and antitumoral activity. Journal of Immunology 180(12): 8176-8183. Shnyder, S.D, Cooper, P.A, Millington, N.J, Gill, J.H & Bibby, M.C (2008). Sodium Pancratistatin 3,4-O-Cyclic Phosphate, a water soluble synthetic derivative of Pancratistatin, is highly effective in a human colon tumour model. Journal of Natural Products 71(3): 321-324. Atkinson, J.M, Siller, C.S & Gill, J.H (2008). Tumour endoproteases: the cutting edge of cancer drug delivery?. British Journal of Pharmacology 153(7): 1344-1352. Behrens, D, Gill, J.H & Fichtner, I (2007). Loss of tumourigenicity of stably ERβ-transfected MCF-7 breast cancer cells. Molecular and Cellular Endocrinology 274(1-2): 19-29. Atkinson, J.M, Pennington, C.J, Martin, S.W, Anikin, V.A, Mearns, A.J, Loadman, P.M, Edwards, D.R & Gill, J.H (2007). Membrane Type Matrix Metalloproteinases (MMPs) Show Differential Expression in Non-small Cell Lung Cancer (NSCLC) Compared to Normal Lung: Correlation of MMP-14 mRNA Expression and Proteolytic Activity. European Journal of Cancer 43(11): 1764-1771. Seargent, J.M, Loadman, P.M, Martin, S.W, Naylor, B, Bibby, M.C & Gill, J.H (2005). Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 65(4): 815-820. Fichtner, I, Slisow, W, Gill, J.H, Becker, M, Elbe, B, Hillebrand, T & Bibby, M.C (2004). Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. European Journal of Cancer 40(2): 298-307. Seargent, J.M, Yates, E.A & Gill, J.H (2004). GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. British Journal of Pharmacology 143(8): 933-937. Basu, S, Brown, J.E, Flannigan, G.M, Gill, J.H, Loadman, P.M, Martin, S.W, Seargent, J.M, Shah, T, Puri, R & Phillips, R.M (2004). Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. International Journal of Cancer 109(5): 703-709. Gill, J.H, Kirwan, I.G, Seargent, J.M, Martin, S.W, Tijani, S, Anikin, V.A, Mearns, A.J, Bibby M.C, Anthoney, A & Loadman, P.M (2004). MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 6(6): 777-785.